End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,55,930 CLP | 0.00% | 0.00% | +14.33% |
11:56am | RTW Biotech portfolio company to sell subsidiary for USD1.25 billion | AN |
08/06 | Top law firms in US opioid lawsuits to get hundreds of millions in fees | RE |
Sales 2024 * | 88.79B 81,978B 7,421B | Sales 2025 * | 92.1B 85,043B 7,698B | Capitalization | 354B 3,26,946B 29,596B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 3.99 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.84 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 1,31,900 |
Yield 2024 * |
3.28% | Yield 2025 * |
3.42% | Free-Float | 77.08% |
Latest transcript on Johnson & Johnson
6 months | +14.33% | ||
Current year | +14.33% |
Managers | Title | Age | Since |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01/89/01 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 01/98/01 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 05/19/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 25/19/25 |
D. Davis
BRD | Director/Board Member | 72 | 19/14/19 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 22/09/22 |
Date | Price | Change |
---|---|---|
10/24/10 | 1,55,930 | 0.00% |
07/24/07 | 1,55,930 | 0.00% |
06/24/06 | 1,55,930 | 0.00% |
05/24/05 | 1,55,930 | 0.00% |
04/24/04 | 1,55,930 | 0.00% |
End-of-day quote Santiago S.E., June 10, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+47.70% | 779B | |
+40.67% | 631B | |
+20.13% | 333B | |
+8.20% | 301B | |
+16.96% | 249B | |
-1.35% | 216B | |
+10.77% | 214B | |
+4.37% | 163B | |
-2.24% | 159B |
- Stock Market
- Equities
- JNJ Stock
- JNJCL Stock